Kevin T Ong1, Victor L Villemagne2, Alex Bahar-Fuchs3, Fiona Lamb1, Narelle Langdon1, Ana M Catafau4, Andrew W Stephens4, John Seibyl5, Ludger M Dinkelborg4, Cornelia B Reininger6, Barbara Putz6, Beate Rohde6, Colin L Masters7, Christopher C Rowe1. 1. Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia. 2. Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia. 3. Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia Centre for Research on Aging, Health, and Wellbeing, The Australian National University, Acton, Australian Capital Territory, Australia. 4. Piramal Imaging GmbH, Berlin, Germany. 5. Molecular NeuroImaging, L.L.C., New Haven, Connecticut, USA. 6. Bayer Healthcare, Berlin, Germany. 7. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Abstract
BACKGROUND: We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. METHODS: 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMCI) was defined by a composite episodic memory (EM) Z-score of <-1.5. RESULTS: At baseline, 24 (53%) MCI were FBB+. Majority reads agreed with SUVR classification (κ 0.96). In 2 years, 18 (75%) FBB+ progressed to AD compared with 2 (9.5%) FBB-, yielding a predictive accuracy of 83% (95% CI 61% to 94%). Four FBB- developed non-AD dementia. Predictive accuracies of HV (58% (95% CI 42% to 73%)) and aMCI status (73% (95% CI 58% to 81%)) were lower. Combinations did not improve accuracy. By 4 years, 21 (87.5%) FBB+ had AD whereas 5 (24%) FBB- had non-AD dementia yielding a predictive accuracy of 94% (95% CI 74% to 99%). While the strong baseline association between FBB SUVR and EM declined over 2 years, the association between EM and HV became stronger. FBB SUVR increased 2.2%/year in FBB+ with no change in FBB-. CONCLUSIONS: (18)F-florbetaben Aβ imaging facilitates accurate detection of prodromal AD. As neurodegeneration progresses, and in contrast with the early stages of the disease, hippocampal atrophy and not Aβ, seems to drive memory decline. TRIAL REGISTRATION NUMBER: NCT01138111. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. METHODS: 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMCI) was defined by a composite episodic memory (EM) Z-score of <-1.5. RESULTS: At baseline, 24 (53%) MCI were FBB+. Majority reads agreed with SUVR classification (κ 0.96). In 2 years, 18 (75%) FBB+ progressed to AD compared with 2 (9.5%) FBB-, yielding a predictive accuracy of 83% (95% CI 61% to 94%). Four FBB- developed non-AD dementia. Predictive accuracies of HV (58% (95% CI 42% to 73%)) and aMCI status (73% (95% CI 58% to 81%)) were lower. Combinations did not improve accuracy. By 4 years, 21 (87.5%) FBB+ had AD whereas 5 (24%) FBB- had non-AD dementia yielding a predictive accuracy of 94% (95% CI 74% to 99%). While the strong baseline association between FBB SUVR and EM declined over 2 years, the association between EM and HV became stronger. FBB SUVR increased 2.2%/year in FBB+ with no change in FBB-. CONCLUSIONS: (18)F-florbetaben Aβ imaging facilitates accurate detection of prodromal AD. As neurodegeneration progresses, and in contrast with the early stages of the disease, hippocampal atrophy and not Aβ, seems to drive memory decline. TRIAL REGISTRATION NUMBER: NCT01138111. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe Journal: Nat Rev Neurol Date: 2018-02-16 Impact factor: 42.937
Authors: S Schönecker; C Prix; T Raiser; N Ackl; E Wlasich; G Stenglein-Krapf; E Mille; M Brendel; O Sabri; M Patt; H Barthel; P Bartenstein; J Levin; A Rominger; A Danek Journal: Nervenarzt Date: 2017-02 Impact factor: 1.214
Authors: Martin J Lan; R Todd Ogden; Dileep Kumar; Yaakov Stern; Ramin V Parsey; Gregory H Pelton; Harry Rubin-Falcone; Gnanavalli Pradhaban; Francesca Zanderigo; Jeffrey M Miller; J John Mann; D P Devanand Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472